

# Joel M Kremer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/801616/publications.pdf>

Version: 2024-02-01

204  
papers

24,506  
citations

13865

67  
h-index

6996

154  
g-index

207  
all docs

207  
docs citations

207  
times ranked

13696  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. New England Journal of Medicine, 1999, 340, 253-259.	27.0	2,044
2	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 625-639.	3.4	1,413
3	Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor $\gamma$ Inhibition. New England Journal of Medicine, 2005, 353, 1114-1123.	27.0	1,157
4	Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4lg. New England Journal of Medicine, 2003, 349, 1907-1915.	27.0	973
5	Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. New England Journal of Medicine, 2012, 367, 495-507.	27.0	826
6	Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. Annals of Internal Medicine, 2006, 144, 865.	3.9	643
7	Methotrexate for Rheumatoid Arthritis. Arthritis and Rheumatism, 1994, 37, 316-328.	6.7	594
8	Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2002, 46, 614-624.	6.7	570
9	Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis. Annals of Internal Medicine, 1987, 106, 497.	3.9	508
10	Dietary fish oil and olive oil supplementation in patients with Rheumatoid Arthritis clinical and immunologic effects. Arthritis and Rheumatism, 1990, 33, 810-820.	6.7	502
11	The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis and Rheumatism, 2009, 60, 1895-1905.	6.7	501
12	Baricitinib in Patients with Refractory Rheumatoid Arthritis. New England Journal of Medicine, 2016, 374, 1243-1252.	27.0	499
13	Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis and Rheumatism, 2013, 65, 559-570.	6.7	481
14	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 924-939.	3.4	466
15	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIB, double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism, 2005, 52, 2263-2271.	6.7	456
16	Toward a better understanding of methotrexate. Arthritis and Rheumatism, 2004, 50, 1370-1382.	6.7	432
17	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. Annals of Internal Medicine, 2013, 159, 253.	3.9	381
18	The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis and Rheumatism, 1986, 29, 822-831.	6.7	379

#	ARTICLE	IF	CITATIONS
19	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. Arthritis and Rheumatism, 2011, 63, 609-621.	6.7	369
20	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1108-1123.	5.6	339
21	Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 2766-2774.	6.7	312
22	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 576-582.	0.9	304
23	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CPâ€690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and Rheumatism, 2012, 64, 970-981.	6.7	293
24	Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. Annals of Internal Medicine, 2002, 137, 726.	3.9	287
25	Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2018, 391, 2503-2512.	13.7	280
26	Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review. Arthritis and Rheumatism, 1997, 40, 1829-1837.	6.7	279
27	Integrated safety in tocilizumab clinical trials. Arthritis Research and Therapy, 2011, 13, R141.	3.5	278
28	Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Annals of the Rheumatic Diseases, 2006, 66, 228-234.	0.9	261
29	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Annals of the Rheumatic Diseases, 2010, 69, 1920-1925.	0.9	255
30	Long-Term Prospective Study of the Use of Methotrexate in the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatism, 1992, 35, 138-145.	6.7	252
31	Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis and Rheumatism, 1999, 42, 1322-1328.	6.7	248
32	nâ~3 Fatty acid supplements in rheumatoid arthritis. American Journal of Clinical Nutrition, 2000, 71, 349S-351S.	4.7	240
33	Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs clinical and immune correlates. Arthritis and Rheumatism, 1995, 38, 1107-1114.	6.7	224
34	Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: Association with hepatic folate deficiency and formation of polyglutamates. Arthritis and Rheumatism, 1986, 29, 832-835.	6.7	207
35	Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 1998, 41, 290-297.	6.7	206
36	Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 3095-3103.	6.7	188

#	ARTICLE	IF	CITATIONS
37	Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 329-335.	6.7	187
38	Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A Prospective Study with Baseline and Sequential Biopsy Samples. <i>Arthritis and Rheumatism</i> , 1989, 32, 121-127.	6.7	178
39	Methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 305-314.	6.7	168
40	Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2001, 134, 695.	3.9	165
41	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	3.4	161
42	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008, 58, 953-963.	6.7	159
43	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
44	Contribution of common polymorphisms in reduced folate carrier and ??-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 733-739.	5.7	155
45	A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. <i>Arthritis and Rheumatology</i> , 2016, 68, 2867-2877.	5.6	149
46	Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 607-612.	6.7	148
47	A long-term prospective study of the use of methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 577-584.	6.7	147
48	A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1134-1142.	0.9	136
49	Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1826-1830.	0.9	134
50	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. <i>PLoS ONE</i> , 2015, 10, e0122271.	2.5	120
51	A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030.	0.9	117
52	Golimumab, a new human anti-tumor necrosis factor Î± antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2010, 62, 917-928.	6.7	116
53	Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIb Study. <i>Journal of Rheumatology</i> , 2009, 36, 736-742.	2.0	114
54	Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. <i>American Journal of Medicine</i> , 1987, 82, 781-786.	1.5	113

#	ARTICLE	IF	CITATIONS
55	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	2.0	108
56	Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 1809-1817.	1.9	101
57	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 489-497.	3.4	99
58	Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations. <i>Arthritis and Rheumatism</i> , 2003, 48, 1493-1499.	6.7	97
59	Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years. <i>Arthritis and Rheumatism</i> , 1997, 40, 984-985.	6.7	91
60	Racial and Ethnic Disparities in Disease Activity in Patients with Rheumatoid Arthritis. <i>American Journal of Medicine</i> , 2013, 126, 1089-1098.	1.5	90
61	Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1612-1617.	0.9	89
62	Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. <i>ACR Open Rheumatology</i> , 2021, 3, 173-184.	2.1	88
63	Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. <i>Journal of Rheumatology</i> , 2013, 40, 113-126.	2.0	87
64	Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. <i>Arthritis and Rheumatology</i> , 2019, 71, 1987-1996.	5.6	87
65	Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. <i>Lipids</i> , 1996, 31, S243-S247.	1.7	86
66	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.9	83
67	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	12.8	73
68	Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 2337-2345.	1.9	71
69	Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. <i>Arthritis Care and Research</i> , 2015, 67, 1671-1678.	3.4	67
70	Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy followup over long treatment intervals and correlation with clinical and laboratory variables. <i>Arthritis and Rheumatism</i> , 1995, 38, 1194-1203.	6.7	65
71	Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study. <i>Journal of Rheumatology</i> , 2012, 39, 2238-2246.	2.0	65
72	Linkage of a Newly Identified United States Rheumatoid Arthritis Registry With Administrative Data to Facilitate Comparative Effectiveness Research. <i>Arthritis Care and Research</i> , 2014, 66, 1790-1798.	3.4	65

#	ARTICLE	IF	CITATIONS
73	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1751-1761.	5.6	65
74	Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. <i>Journal of Rheumatology</i> , 2004, 31, 1521-31.	2.0	65
75	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	5.6	64
76	The CORRONA database. <i>Autoimmunity Reviews</i> , 2006, 5, 46-54.	5.8	63
77	Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 592-598.	3.4	62
78	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 430-436.	0.9	61
79	Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study. <i>Journal of Rheumatology</i> , 2009, 36, 1611-1617.	2.0	60
80	Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate. <i>Arthritis and Rheumatism</i> , 2003, 48, 2763-2768.	6.7	56
81	Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371.	3.4	56
82	A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 170-176.	0.9	55
83	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	3.5	53
84	Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 935-944.	1.5	51
85	Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry. <i>Rheumatology and Therapy</i> , 2017, 4, 489-502.	2.3	51
86	Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry. <i>Arthritis Care and Research</i> , 2011, 63, 856-864.	3.4	49
87	Chronic Opioid Use in Rheumatoid Arthritis: Prevalence and Predictors. <i>Arthritis and Rheumatology</i> , 2019, 71, 670-677.	5.6	49
88	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 900-908.	1.9	47
89	Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 95.	3.5	46
90	Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 256.	3.5	46



#	ARTICLE	IF	CITATIONS
91	Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. <i>RMD Open</i> , 2016, 2, e000287.	3.8	46
92	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naïve patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1522-1529.	0.9	46
93	Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort. <i>Arthritis Care and Research</i> , 2011, 63, 1672-1679.	3.4	43
94	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 943-952.	5.6	42
95	Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor- $\alpha$ Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. <i>Journal of Rheumatology</i> , 2018, 45, 32-39.	2.0	42
96	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 988-995.	0.9	41
97	Leflunomide. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 295-309.	1.9	39
98	Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab. <i>Arthritis and Rheumatology</i> , 2018, 70, 1200-1208.	5.6	39
99	Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012, 64, 1811-1818.	3.4	38
100	Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 1-9.	1.5	38
101	Selective Costimulation Modulators. <i>Journal of Clinical Rheumatology</i> , 2005, 11, S55-S62.	0.9	37
102	Combination therapy with biologic agents in rheumatoid arthritis: Perils and promise. <i>Arthritis and Rheumatism</i> , 1998, 41, 1548-1551.	6.7	35
103	Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort. <i>American Journal of Medicine</i> , 2008, 121, 532-538.	1.5	32
104	Comparative Analysis of Disease Activity Measures, Use of Biologic Agents, Body Mass Index, Radiographic Features, and Bone Density in Psoriatic Arthritis and Rheumatoid Arthritis Patients Followed in a Large U.S. Disease Registry. <i>Journal of Rheumatology</i> , 2010, 37, 2566-2572.	2.0	31
105	Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0210459.	2.5	31
106	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	2.0	31
107	Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial. <i>Journal of Rheumatology</i> , 2014, 41, 1077-1087.	2.0	29
108	Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2019, 6, 573-586.	2.3	29

#	ARTICLE	IF	CITATIONS
109	Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. Chinese Medical Journal, 2018, 131, 2683-2692.	2.3	28
110	Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis and Rheumatism, 2005, 53, 12-17.	6.7	27
111	Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology, 2009, 48, 686-690.	1.9	26
112	Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. BMC Musculoskeletal Disorders, 2014, 15, 113.	1.9	26
113	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International Journal of Rheumatic Diseases, 2016, 19, 1216-1225.	1.9	26
114	Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial. Seminars in Arthritis and Rheumatism, 2021, 51, 831-838.	3.4	26
115	Treatment of rheumatoid arthritis with etanercept. Rheumatic Disease Clinics of North America, 2004, 30, 311-328.	1.9	25
116	The role of drug and disease registries in rheumatic disease epidemiology. Current Opinion in Rheumatology, 2008, 20, 123-130.	4.3	25
117	Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 908-910.	0.9	25
118	Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes. European Journal of Human Genetics, 2016, 24, 263-270.	2.8	25
119	Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Research and Therapy, 2016, 18, 280.	3.5	23
120	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open, 2020, 6, e001370.	3.8	23
121	Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clinical and Experimental Rheumatology, 2016, 34, 430-42.	0.8	23
122	The Corrona US registry of rheumatic and autoimmune diseases. Clinical and Experimental Rheumatology, 2016, 34, S96-S99.	0.8	23
123	Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. Arthritis and Rheumatism, 1987, 30, 369-374.	6.7	22
124	Electron microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis. Correlation with light microscopic findings. Arthritis and Rheumatism, 1989, 32, 1202-1213.	6.7	22
125	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clinical Rheumatology, 2018, 37, 2331-2340.	2.2	22
126	Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. Journal of Rheumatology, 2015, 42, 1090-1098.	2.0	21



#	ARTICLE	IF	CITATIONS
127	One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. <i>Arthritis Research and Therapy</i> , 2018, 20, 2.	3.5	21
128	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 310-319.	1.9	19
129	Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 472-477.	3.4	19
130	Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 775-792.	2.3	19
131	Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. <i>Rheumatology and Therapy</i> , 2019, 6, 217-230.	2.3	18
132	Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 625-33.	0.8	18
133	Every-other-week methotrexate in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 601-607.	6.7	17
134	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015, 1, e000037.	3.8	17
135	Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 381-391.	1.9	16
136	Methotrexate treatment of rheumatic diseases: Can we do better?. <i>Arthritis and Rheumatism</i> , 2008, 58, 3279-3282.	6.7	16
137	Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. <i>Inflammation</i> , 2013, 36, 279-284.	3.8	16
138	A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?. <i>Clinical Rheumatology</i> , 2017, 36, 1215-1220.	2.2	16
139	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- $\alpha$ Inhibitors: The NETWORK-004 Prospective Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1159-1176.	2.3	16
140	Xanthomatous infiltration of ankle tendons. <i>Skeletal Radiology</i> , 1997, 26, 256-259.	2.0	15
141	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 2238-2246.	2.0	14
142	Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 405-417.	2.3	13
143	Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry. <i>Clinical Rheumatology</i> , 2015, 34, 1697-1704.	2.2	12
144	Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 163-166.	3.4	12

#	ARTICLE	IF	CITATIONS
145	Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2016, 43, 1027-1029.	2.0	12
146	Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry. <i>Rheumatology and Therapy</i> , 2017, 4, 375-389.	2.3	12
147	Interpreting registry-derived drug studies: Does societal context matter?. <i>Arthritis and Rheumatism</i> , 2009, 60, 3155-3157.	6.7	11
148	Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. <i>Clinical Rheumatology</i> , 2017, 36, 2135-2140.	2.2	11
149	Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2018, 5, 507-523.	2.3	11
150	Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 165-169.	3.4	10
151	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1114-1124.	3.4	10
152	Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab. <i>Journal of Rheumatology</i> , 2011, 38, 2572-2580.	2.0	9
153	OP0028...POST-APPROVAL COMPARATIVE SAFETY STUDY OF TOFACITINIB AND BIOLOGIC DMARDS: FIVE-YEAR RESULTS FROM A US-BASED RHEUMATOID ARTHRITIS REGISTRY. , 2019, , .		9
154	Methotrexate Pulmonary Toxicity: Deep Inspiration. <i>Arthritis and Rheumatology</i> , 2020, 72, 1959-1962.	5.6	9
155	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200692.	2.0	9
156	Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1909-1916.	3.4	9
157	Lack of a renal-protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin a. results of a randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 1994, 37, 1321-1325.	6.7	8
158	Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry. <i>Rheumatology and Therapy</i> , 2015, 2, 153-164.	2.3	8
159	Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. <i>Journal of Rheumatology</i> , 2016, 43, 924-930.	2.0	8
160	Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry. <i>Rheumatology and Therapy</i> , 2016, 3, 103-115.	2.3	8
161	Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry. <i>Rheumatology International</i> , 2020, 40, 1239-1248.	3.0	8
162	Physician Prescribing Patterns and Risk of Future Long-Term Opioid Use Among Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 1082-1090.	5.6	8

#	ARTICLE	IF	CITATIONS
163	Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskeletal Disorders, 2012, 13, 85.	1.9	7
164	Use of health plan combined with registry data to predict clinical trial recruitment. Clinical Trials, 2014, 11, 96-101.	1.6	7
165	Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. Journal of Rheumatology, 2018, 45, 1353-1360.	2.0	7
166	TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study. ACR Open Rheumatology, 2022, 4, 65-73.	2.1	7
167	Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry. American Health and Drug Benefits, 2018, 11, 148-158.	0.5	7
168	Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in jurkat T cells. International Journal of Immunopharmacology, 1998, 19, 709-720.	1.1	6
169	Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 127-136.	2.0	6
170	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology, 2020, 38, 848-857.	0.8	6
171	Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 2275-2280.	2.2	5
172	Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis. ACR Open Rheumatology, 2020, 2, 255-260.	2.1	5
173	COMET's path, and the new biologicals in rheumatoid arthritis. Lancet, The, 2008, 372, 347-348.	13.7	4
174	Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. Rheumatology and Therapy, 2020, 7, 357-369.	2.3	4
175	Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. Rheumatology International, 2021, 41, 585-593.	3.0	4
176	Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. International Immunopharmacology, 2021, 91, 107260.	3.8	4
177	Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open, 2020, 6, e001389.	3.8	4
178	New EULAR guidelines for RA: a job well done. Nature Reviews Rheumatology, 2014, 10, 6-8.	8.0	3
179	Still Trying to Understand Methotrexate. Journal of Rheumatology, 2014, 41, 2099-2101.	2.0	3
180	Can Methotrexate Prevent Knee Arthroplasties in Patients with Rheumatoid Arthritis?. Journal of Rheumatology, 2015, 42, 2217-2218.	2.0	3

#	ARTICLE	IF	CITATIONS
181	Fish Oil and Inflammation – A Fresh Look. Journal of Rheumatology, 2017, 44, 713-716.	2.0	3
182	Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	3
183	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 97-101.	1.6	3
184	Weight Fluctuation and the Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis. Arthritis Care and Research, 2020, , .	3.4	3
185	Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: Comment on the article by Stamp et al. Arthritis and Rheumatism, 2010, 62, 2559-2560.	6.7	2
186	Applying biologic therapies to the management of patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2014, 43, 577.	3.4	2
187	Bias? Not so fast. Annals of the Rheumatic Diseases, 2016, 75, 1581-1582.	0.9	2
188	Design characteristics of the Corrona Japan rheumatoid arthritis registry. Modern Rheumatology, 2018, 28, 95-100.	1.8	2
189	Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 2501-2508.	2.2	2
190	Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy. Journal of Rheumatology, 2020, 47, 325-332.	2.0	2
191	Etanercept for patients with RA: more is not always better. Nature Clinical Practice Rheumatology, 2009, 5, 10-11.	3.2	1
192	A phase III randomised placebo-controlled double-blind study of upadacitinib (ABT-494), a selective JAK-1 Inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs. Rheumatology, 2018, 57, .	1.9	1
193	Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice. Rheumatology and Therapy, 2019, 6, 421-433.	2.3	1
194	Methotrexate and Cardiovascular Disease in Patients With Rheumatoid Arthritis: Insights and Novel Speculations. Journal of Rheumatology, 2021, 48, 793-795.	2.0	1
195	Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey. Rheumatology International, 2022, 42, 1555-1564.	3.0	1
196	Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?. Arthritis and Rheumatism, 2005, 53, 636-638.	6.7	0
197	Rheumatoid arthritis – is methotrexate re-employment an effective treatment option?. Nature Clinical Practice Rheumatology, 2006, 2, 246-247.	3.2	0
198	Does DMARD treatment slow or prevent development of RA in patients with UA?. Nature Clinical Practice Rheumatology, 2007, 3, 690-691.	3.2	0

#	ARTICLE	IF	CITATIONS
199	FRI0155â€¦A COMPARISON OF UPADACITINIB PLUS METHOTREXATE AND UPADACITINIB PLUS OTHER CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ANALYSIS OF TWO PHASE 3 STUDIES. , 2019, , .		0
200	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Antiâ€¦Inflammatory Drug Users: Realâ€¦World Application. ACR Open Rheumatology, 2020, 2, 269-275.	2.1	0
201	Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry. Rheumatology and Therapy, 2021, 8, 467-481.	2.3	0
202	Dr. Kremer et al reply. Journal of Rheumatology, 2021, , jrheum.210992.	2.0	0
203	Rheumatoid arthritis: a rapidly evolving treatment paradigm. Managed Care Interface, 2007, 20, 17, 24.	0.2	0
204	New and emerging therapies for rheumatoid arthritis. Rheumatic Disease Clinics of North America, 2004, 30, xi-xii.	1.9	0